| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
76,182,000 |
| Market
Cap: |
13.21(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$127.77 - $330.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 882 |
| Guru Rank Value : 0.1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Insulet is primarily engaged in the development, manufacture and sale of its proprietary Omnipod® System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes: the Omnipod Insulin Management System and the Omnipod DASH™ Insulin Management System, its digital mobile Omnipod platform. The Omnipod System features: a small, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body; and the Personal Diabetes Manager, a wireless, handheld device that programs the Pod with the user's personalized insulin-delivery instructions and, wirelessly monitors the Pod's operation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
5,551 |
8,851 |
| Total Buy Value |
$0 |
$0 |
$1,006,995 |
$2,012,670 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
2 |
3 |
| Total Shares Sold |
3,300 |
14,981 |
52,044 |
170,562 |
| Total Sell Value |
$596,970 |
$2,503,218 |
$8,850,279 |
$40,925,357 |
| Total People Sold |
1 |
3 |
5 |
8 |
| Total Sell Transactions |
1 |
3 |
8 |
21 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sommer Regina O |
Director |
• • – |
2016-05-25 |
4 |
S |
$30.42 |
$243,924 |
D/D |
(8,019) |
20,330 |
|
- |
|
| Sullivan Patrick J |
President & CEO |
• • – |
2016-05-18 |
4 |
B |
$26.90 |
$403,563 |
D/D |
15,000 |
217,795 |
2.81 |
- |
|
| Sullivan Patrick J |
President & CEO |
• • – |
2016-05-17 |
4 |
B |
$27.05 |
$811,620 |
D/D |
30,000 |
202,795 |
2.81 |
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2016-05-13 |
4 |
B |
$26.63 |
$79,222 |
D/D |
2,975 |
51,315 |
2.74 |
- |
|
| Lemoine David A |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
10,220 |
|
- |
|
| Crawford Sally |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
21,849 |
|
- |
|
| Hopfield Jessica |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
12,648 |
|
- |
|
| Scannell Timothy J |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
15,930 |
|
- |
|
| Sommer Regina O |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
28,349 |
|
- |
|
| Zakrzewski Joseph S |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
27,849 |
|
- |
|
| Fallon John A. |
Director |
• • – |
2016-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,810 |
15,849 |
|
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2016-05-05 |
4 |
B |
$30.13 |
$49,890 |
D/D |
1,656 |
48,340 |
2.74 |
- |
|
| Levitz Michael L |
SVP and CFO |
• • – |
2016-05-04 |
4 |
D |
$30.25 |
$141,237 |
D/D |
(4,669) |
48,612 |
|
- |
|
| Levangie Daniel J |
EVP & President, Drug Delivery |
• • – |
2016-04-30 |
4 |
D |
$33.30 |
$21,712 |
D/D |
(652) |
21,122 |
|
- |
|
| Thomas Bradley A |
EVP Human Resources |
• • – |
2016-04-01 |
4 |
D |
$33.52 |
$24,805 |
D/D |
(740) |
46,684 |
|
- |
|
| Petrovic Shacey |
President, Diabetes Products |
• • – |
2016-04-01 |
4 |
D |
$33.52 |
$24,805 |
D/D |
(740) |
78,782 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-04-01 |
4 |
D |
$33.52 |
$24,805 |
D/D |
(740) |
21,774 |
|
- |
|
| Abdel-Malek Aiman |
SVP, Advanced Technology |
• • – |
2016-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
14,022 |
14,022 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-10 |
4 |
S |
$30.65 |
$144,024 |
D/D |
(4,699) |
22,514 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-10 |
4 |
OE |
$15.14 |
$143,149 |
D/D |
9,455 |
27,213 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-09 |
4 |
S |
$31.04 |
$235,904 |
D/D |
(7,600) |
17,758 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-09 |
4 |
OE |
$15.14 |
$235,351 |
D/D |
15,545 |
25,358 |
|
- |
|
| Levangie Daniel J |
President, Drug Delivery |
• • – |
2016-03-07 |
4 |
S |
$31.15 |
$238,702 |
D/D |
(7,663) |
9,813 |
|
- |
|
| Hopfield Jessica |
Director |
• • – |
2016-03-02 |
4 |
B |
$30.91 |
$99,839 |
D/D |
3,230 |
8,838 |
2.39 |
- |
|
| Spears Michael P |
SVP, Quality and Regulatory |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,253 |
32,684 |
|
- |
|
1133 Records found
|
|
Page 24 of 46 |
|
|
3.15 (1.85%) 
